Overview

• BLZ945, originally developed for brain cancer, targets immune cells harboring HIV in the brain.
• The drug reduced viral DNA in the brain by up to 99% in treated monkeys.
• Current HIV treatments struggle to penetrate the brain's defenses, leaving viral reservoirs.
• This approach could improve cognitive health in HIV patients by addressing brain-related issues.
• Further research will test the drug in combination with antiretroviral therapy.